Related references
Note: Only part of the references are listed.siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes
Shigeo Matsuda et al.
ACS CHEMICAL BIOLOGY (2015)
Hepatocyte-Specific Delivery of siRNAs Conjugated to Novel Non-nucleosidic Trivalent N-Acetylgalactosamine Elicits Robust Gene Silencing in Vivo
Kallanthottathil G. Rajeev et al.
CHEMBIOCHEM (2015)
Protease-triggered siRNA delivery vehicles
David B. Rozema et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Dysregulation of microRNA biogenesis and gene silencing in cancer
Akiko Hata et al.
SCIENCE SIGNALING (2015)
Dysregulation of microRNA biogenesis and gene silencing in cancer
Akiko Hata et al.
SCIENCE SIGNALING (2015)
Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates
Trinna L. Cuellar et al.
NUCLEIC ACIDS RESEARCH (2015)
Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity
Alexey Berezhnoy et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors
Beate Schultheis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer
Christopher L. Daige et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
Knockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo
Henryk Dudek et al.
MOLECULAR THERAPY (2014)
Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications
Bryan R. Meade et al.
NATURE BIOTECHNOLOGY (2014)
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Hao Yin et al.
NATURE BIOTECHNOLOGY (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
Antisense oligonucleotides: modifications and clinical trials
Vivek K. Sharma et al.
MEDCHEMCOMM (2014)
Toxicity profiling of several common RNAi-based nanomedicines: a comparative study
Dalit Landesman-Milo et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2014)
The mTOR pathway in hepatic malignancies
Mamatha Bhat et al.
HEPATOLOGY (2013)
Novel Hydrophobically Modified Asymmetric RNAi Compounds (sd-rxRNA) Demonstrate Robust Efficacy in the Eye
Michael Byrne et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2013)
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Martin A. Maier et al.
MOLECULAR THERAPY (2013)
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Christine I. Wooddell et al.
MOLECULAR THERAPY (2013)
Efficient and specific gene knockdown by small interfering RNAs produced in bacteria
Linfeng Huang et al.
NATURE BIOTECHNOLOGY (2013)
Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape
Jerome Gilleron et al.
NATURE BIOTECHNOLOGY (2013)
Delivery materials for siRNA therapeutics
Rosemary Kanasty et al.
NATURE MATERIALS (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Josep Tabernero et al.
CANCER DISCOVERY (2013)
Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles
Tomoko Nakayama et al.
MOLECULAR THERAPY (2012)
Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion
Teresa L. M. Thurston et al.
NATURE (2012)
Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis
Yan-dan Yao et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras
Lee Adam Wheeler et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Biodistribution of Small Interfering RNA at the Organ and Cellular Levels after Lipid Nanoparticle-mediated Delivery
Bin Shi et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2011)
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Lydia Alvarez-Erviti et al.
NATURE BIOTECHNOLOGY (2011)
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Nathalie M. Goemans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation
Ranit Kedmi et al.
BIOMATERIALS (2010)
Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA
Luigi Warren et al.
CELL STEM CELL (2010)
Targeting Polo-like Kinase in Cancer Therapy
Yan Degenhardt et al.
CLINICAL CANCER RESEARCH (2010)
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
Thomas W. Geisbert et al.
LANCET (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Akin Akinc et al.
MOLECULAR THERAPY (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
Rational design of cationic lipids for siRNA delivery
Sean C. Semple et al.
NATURE BIOTECHNOLOGY (2010)
Durable Protection from Herpes Simplex Virus-2 Transmission Following Intravaginal Application of siRNAs Targeting Both a Viral and Host Gene
Yichao Wu et al.
CELL HOST & MICROBE (2009)
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Adam D. Judge et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
Marcin Kortylewski et al.
NATURE BIOTECHNOLOGY (2009)
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice
Priti Kumar et al.
CELL (2008)
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Mark E. Kleinman et al.
NATURE (2008)
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akin Akinc et al.
NATURE BIOTECHNOLOGY (2008)
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma
Hendrik Poeck et al.
NATURE MEDICINE (2008)
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target
Dan Peer et al.
SCIENCE (2008)
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
Derek W. Bartlett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
David B. Rozema et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1
Dan Peer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras
James O. McNamara et al.
NATURE BIOTECHNOLOGY (2006)
Widespread siRNA off-target'' transcript silencing mediated by seed region sequence complementarity
Aimee L. Jackson et al.
RNA (2006)
Position-specific chemical modification of siRNAs reduces off-target'' transcript silencing
Aimee L. Jackson et al.
RNA (2006)
RNAi-mediated gene silencing in non-human primates
TS Zimmermann et al.
NATURE (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
A Birmingham et al.
NATURE METHODS (2006)
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo
AD Judge et al.
MOLECULAR THERAPY (2006)
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging
DW Bartlett et al.
NUCLEIC ACIDS RESEARCH (2006)
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
DV Morrissey et al.
NATURE BIOTECHNOLOGY (2005)
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
EW Song et al.
NATURE BIOTECHNOLOGY (2005)
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication
DV Morrissey et al.
HEPATOLOGY (2005)
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
AD Judge et al.
NATURE BIOTECHNOLOGY (2005)
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
V Hornung et al.
NATURE MEDICINE (2005)
Cutting edge: Species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified ohgonucleotides
TL Roberts et al.
JOURNAL OF IMMUNOLOGY (2005)
Rational siRNA design for RNA interference
A Reynolds et al.
NATURE BIOTECHNOLOGY (2004)
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J Soutschek et al.
NATURE (2004)
siRNA function in RNAi: A chemical modification analysis
YL Chiu et al.
RNA (2003)
Expression profiling reveals off-target gene regulation by RNAi
AL Jackson et al.
NATURE BIOTECHNOLOGY (2003)
RNA interference targeting Fas protects mice from fulminant hepatitis
EW Song et al.
NATURE MEDICINE (2003)
Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules
DB Rozema et al.
BIOCONJUGATE CHEMISTRY (2003)
Analysis of gene function in somatic mammalian cells using small interfering RNAs
SM Elbashir et al.
METHODS (2002)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
SM Elbashir et al.
NATURE (2001)
Share Paper
